Neurocrine presents two-year data on CAH treatment Crenessity

Cevap yazmak için giriş yap yada kayıt ol.
Benzer konular Forum Tarih
A Rezolute presents expanded Phase 3 data for hyperinsulinism drug Hisse Senetleri 0 3
A Sutro presents preclinical data on ADC pipeline at AACR meeting Hisse Senetleri 0 4
A Monopar presents Phase 3 Wilson disease trial data at AAN meeting Hisse Senetleri 0 4
A Oppenheimer raises Neurocrine Biosciences price target on acquisition Hisse Senetleri 0 16
A Neurocrine to buy Soleno Therapeutics for $2.9 billion Hisse Senetleri 0 15
A Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook Hisse Senetleri 0 19
A Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises Hisse Senetleri 0 20
A Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright Hisse Senetleri 0 28

Benzer konular

Üst